Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future.
Monoclonal-antibody has been used for patients with autoimmune disorders for several years, and efficacy and safety were appreciated for these patients. Neuromyelitis optica specturm disorder (NMOSD) has been defined as an autoimmune demyelination disorder of the central nervous system (CNS) with a course of relapse-remission. Treatment of prevention is important for patients with NMOSD because of the increased disability after several attacks. Multiple factors were involved in the pathogenesis of NMOSD. Currently, targeting specific factor was favored in the research into the treatment for NMOSD. Previous studies reported the efficacy and tolerance in NMOSD for drugs such as rituximab, tocilizumab, and eculizumab. The aim of this article is to review the current monoclonal therapies for NMOSD patients, and also future alternative options.
a Department of Neurology , The First Affiliated Hospital of Wenzhou Medical University , Wenzhou , Zhejiang , China.
Jie
J
Lin
b Department of Anesthesiology , The First Affiliated Hospital of Wenzhou Medical University , Zhejiang , Wenzhou , China.
Binbin
B
Xue
a Department of Neurology , The First Affiliated Hospital of Wenzhou Medical University , Wenzhou , Zhejiang , China.
Xiang
X
Li
a Department of Neurology , The First Affiliated Hospital of Wenzhou Medical University , Wenzhou , Zhejiang , China.
Junhui
J
Xia
D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000378:metabolism / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000276:immunology / Q000378:metabolism / Q000627:therapeutic use; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D005544:Forecasting; D006801:Humans; D007167:Immunotherapy / Q000379:methods / Q000639:trends; D009471:Neuromyelitis Optica / Q000188:drug therapy* / Q000276:immunology* / Q000378:metabolism
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C481642:eculizumab; C502936:tocilizumab
Neuromyelitis optica spectrum disorder; eculizumab; monoclonal antibody; rituximab; tocilizumab